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Letter to the Editors – Brief papers about basic research or clinical experiences
Kidney transplant recipients infected with
blaKPC-2-producing Klebsiella pneumoniaePacientes trasplantados renales con infección por Klebsiella
2pneumoniae productora de blaKPC-
Dear Editor:
Gram-negative enterobacteria resistant to carbapenem pose
a problem, as this antibiotic is usually used for infections
caused by Enterobacteriaceae producing extended spectrum
-lactamases.1 Klebsiella pneumoniae carbapenemase (KPC)
enzymes are the most common class A carbapenemases.2 We
have reported the ﬁrst cases of blaKPC-2-producing K. pneumo-
niae (KPC-Kp) in kidney transplant patients in our center.3 We
describe the treatment and outcomes of 13 new patients.
This retrospective cohort study was conducted at Hospi-
tal Alemán, Buenos Aires, Argentina. In the study period
(1/2011–8/2013), 93 renal transplants were performed.
Disk diffusion antimicrobial susceptibility tests were per-
formed according to the Clinical and Laboratory Standards
Institute guidelines. KPC was screened with double-disk
diffusion synergy tests; a disk containing 300-g phenyl
boronic acid and a disk containing 10-g imipenem, 10-g
meropenem, or 10-g ertapenem. The modiﬁed pheno-
typic Hodge test was performed for isolates exhibiting
reduced susceptibility to imipenem or meropenem on
the disk diffusion test. blaKPC-2 was conﬁrmed by PCR
with primers KPC-F (5′-ATGTCACTGTATCGCCGTCT-3′) and
KPC-R (5′-TTTTCAGAGCCTTACTGCCC-3′), heat-extracted
DNA as template. Molecular typing was performed using
pulsed-ﬁeld gel electrophoresis, XbaI restriction enzyme;
with strain sequence type 258 clone as reference. Tested
antibiotics: ampicillin, ampicillin/sulbactam, amoxi-
cillin/clavulanic acid, cephalothin, piperacillin/tazobactam,
cefotaxime, ceftazidime, imipenem, meropenem, ertapenem,
gentamicin, amikacin, ciproﬂoxacin, doxycycline, trimetho-
prim/sulfamethoxazole, nitrofurantoin, and fosfomycin.
Tigecycline susceptibility was tested by disk diffusion
(susceptible ≥19mm, intermediate 15–18mm, and resistant
≤14mm). The isolates intermediate or resistant ondisk testing
were conﬁrmed using MIC plates. Polymyxin B susceptibility
was determined with Etest® (bioMérieux, Marcy l’Etoile).
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http://dx.doi.org/10.1016/j.nefro.2015.02.002.Twenty-ﬁve KPC-Kp infectious episodes were documented
in 13 renal transplant recipients. Mean age was 55.84±13.84
years, 9 (62%) patients were female, and the most frequent
primary kidney diseases were diabetes, polycystic kidney dis-
ease. All patients received antibiotic prophylactic therapy
and induction therapy; 12/13 (92.3%) with thymoglobulin and
1/13 with basiliximab. Nine (69%) patients had been in the
intensive care unit (ICU) within 30 days before their ﬁrst infec-
tion, median time of stay was 4 days (0–66 days). Six (46%)
patients showed surgical complications, 10/13 (77%) patients
had delayed graft function, 9/13 (69%) patients had a central
venous catheter and 8/13 (61%) had a urinary catheter for
≥5 days within 3 months before infection. The median time
between transplant and the ﬁrst infection was 79 (8–902) days.
Six (46%) patients had more than two infections, totaling 25
infectious episodes (Table 1).
In all episodes, the site of infection was the urinary tract
and some antibiotic had been administered within 30 days
before diagnosis; however, in 10/25 (40%) episodes, the blood
culture showed positive results. The most frequent antibiotics
in which bacteria were susceptible were fosfomycin (68%),
tigecycline (56%), and colistin (28%). In 1 case, the organism
was not susceptible to any tested antibiotic, and in 3/25 (12%)
cases, itwas susceptible to onedrug.Monotherapywasused in
9/25 (36%) episodes; two drugs were used in 10/25 (40%), three
in 5/25 (20%), and four in 1/25 (4%) episodes. Table 2 shows the
antibiotics used. Tigecycline, alone or combined, resulted in
an unsuccessful outcome. The median treatment time was 21
(14–56) days. Four (31%) patients died as a result of infection.
Discussion: Transplant recipients share risk factors for
infections with resistant bacteria.4 In a report describing an
outbreakofKPC-Kp in transplant patients, infection rateswere
17%, 13%, and 26% in heart, liver, and kidney transplant recip-
5ients, respectively. In our cases, the infection rate was 16%
and strain sequence type 258.
The best treatment for KPC has not been established,
and we could not identify a successful treatment. Before
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Table 1 – Patientsc´haracteristics and outcomes.
Patient Age,
year
Sex Base disease Days between
transplant and
ﬁrst infection
Agent used in
induction
therapy
Days in ICU
(last 3 months
prior to ﬁrst
infection)
Positive
blood
culture
Central
venous
catheter
Urinary
catheter for
≥5 days
DGF Complication Number of
infection
episodes
Outcome
1 48 Male Polycistic kidney
disease
660 Thymoglobulin 0 No No No Yes None 1 Successful
2 46 Female Unknown 902 Thymoglobulin 0 No No No Yes None 2 Successful
3 69 Female Diabetes 295 Thymoglobulin 0 Yes Yes Yes No None 4 Successful
4 67 Female Nephroangioscloris 127 Thymoglobulin 0 No No Yes No None 1 Successful
5 62 Male Diabetes 21 Thymoglobulin 10 Yes Yes Yes Yes Urinary ﬁstula 4 Successful
6 51 Female Polycistic kidney
disease
79 Thymoglobulin 10 Yes Yes Yes Yes Fistula and
peritonitis
1 Died
7 50 Female Unknown 20 Thymoglobulin 4 No Yes Yes Yes Fluid collection 1 Died
8 74 Male Amyloidosis 22 Thymoglobulin 4 No Yes Yes Yes Urinary ﬁstula 3 Successful
9 66 Male Nephroangioesclorosis 66 Thymoglobulin 24 Yes Yes No Yes None 1 Died
10 68 Female Diabetes 8 Basiliximab 7 No Yes Yes Yes Wound dehiscence 3 Successful
11 33 Female Unknown 28 Thymoglobulin 4 No Yes No No None 2 Successful
12 31 Female Systemic lupus
erythematosus
100 Thymoglobulin 10 Yes No No Yes Hematoma 1 Successful
13 61 Female Nephroangiosclorosis 626 Thymoglobulin 66 Yes Yes Yes Yes None 1 Died
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Table 2 – Infection episodes, susceptibility patterns, treatments and outcomes.
Patient Infection
episode
Colonization
before infection
Time from
transplant to
infection
Susceptibility
proﬁle
Treatment CST MIC (mg/l) MEM MIC (mg/l) Duration of
treatment (days)
Time from
isolation to drug
administration
(days)
Outcome
1 15 Yes 660 FOS TIG FOS 32.0 21 3 Reinfection
2 16 No 902 FOS TIG CST FOS 0.5 21 3 Reinfection
17 949 FOS TIG AMK DOX FOS DOX 16.0 21 0 Reinfection
3 18 Yes 295 TIG FOS CST TIG FOS 0.25 14 3 Reinfection
19 389 FOS DOX CST DOX 0.12 14 8 Reinfection
20 437 DOX FOS TIG CST DOX 0.25 8 21 0 Reinfection
21 522 DOX FOS CST FOS DOX 0.25 2 21 0 Successful
4 22 No 127 FOS CST FOS CST 0.25 15 3 Successful
5 23 Yes 21 FOS TIG CST TIG CST 1.0 20 0 Reinfection
24 57 TIG FOS TIG CST 32.0 18 0 Reinfection
25 85 FOS FOS >64 42 2 Reinfection
26 288 DOX DOX CST MEM 4 8 42 0 Successful
6 27 No 79 FOS DOX TIG GEN MEM 0.12 0.5 43 0 Patient died
7 28 No 20 FOS TIG TIG 0.12 28 2 Patient died
8 29 No 22 DOX FOS GEN TIG DOX 16.0 4 15 0 Reinfection
30 40 FOS GEN TIG MEM FOS 8.0 8 25 0 Reinfection
31 82 None CST 4.0 8 15 0 Successful
9 32 Yes 230 GEN TIG T-S AMK FOS MEM CST 20 0 Patient died
10 33 No 68 FOS AMK NFT TIG CST MEM FOS 1.0 0.5 14 0 Reinfection
34 103 FOS DOX CST MEM FOS CST DOX 1.0 8 15 0 Reinfection
35 143 AMK NFT MEM FOS >4 >8 21 0 Successful
11 36 NA 28 DOX FOS GA MEM DOX 1 14 0 Reinfection
37 98 DOX FOS GA DOX MEM FOS 0.12 56 0 Successful
12 38 NA 100 TIG CST TIG MEM CST 0.25 2 41 0 Reinfection
13 39 NA 626 FOS TIG DOX FOS TIG DOX 8.0 16 40 2 Patient died
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btaining susceptibility, empirical treatment was adminis-
ered; a frequent reported combination therapy is tigecycline
lus colistin, but the empirical use of colistin could contribute
o selection of resistant strains.6 We avoided nephrotoxic
gents, and took into consideration the drug concentration
t the site of infection and potential adverse events. Car-
apenem monotherapy has a higher rate of treatment failure
ompared to combination therapy; moreover, only the com-
ination of meropenem, colistin, and tigecycline is associated
ith improved survival in patientswith blood infections.6 Col-
stinewas successfulwhen the isolate showed resistance to all
ested antibiotics. The use of a triple-drug regimen including
igecycline, colistin, and meropenem was linked to a reduced
isk of death.7
Toprevent the spreadof bacteria,measures suchasperirec-
al surveillance swabs, susceptibility tests, use of gowns and
loves, and strict hand hygiene were followed. Also, recipients
f kidneys from living donors were transferred from the oper-
ting room to a non-intensive setting, or underwent a reduced
tay in the ICU. Despite its limitations, this report shows that
TIs caused by KPC-Kp pose a threat to kidney transplant
atients.
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lence; Labrador et al. performed 13,784 SCR measurements in
patients over the age of 18. Findings were the following: UF
<60ml/min/1.73m2 in 1042 patients, out of which 418 resulted
